Clinical Characteristics and Risk Factors for Critically Ill Patients with Carbapenem-Resistant Klebsiella pneumoniae (CrKP): A Cohort Study from Developing Country
Ying-Yi Luan,Yan-Hong Chen,Xue Li,Zhi-Peng Zhou,Jia-Jia Huang,Zhen-Jia Yang,Jing-Jing Zhang,Ming Wu
DOI: https://doi.org/10.2147/IDR.S343489
2021-12-20
Infection and Drug Resistance
Abstract:Ying-Yi Luan, 1, &ast Yan-Hong Chen, 2, &ast Xue Li, 3 Zhi-Peng Zhou, 2 Jia-Jia Huang, 2, 4 Zhen-Jia Yang, 2, 4 Jing-Jing Zhang, 2, 5 Ming Wu 2, 4, 6 1 Department of Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, People's Republic of China; 2 Department of Critical Care Medicine and Hospital Infection Prevention and Control, Shenzhen Second People`s Hospital & First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen, 518035, People's Republic of China; 3 Department of Emergency, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518033, People's Republic of China; 4 Shantou University Medical College, Shantou, 515041, People's Republic of China; 5 Department of Critical Care Medicine, Pingshan District People's Hospital of Shenzhen, Shenzhen, 518118, People's Republic of China; 6 Guangxi University of Chinese Medicine, Nanning, 530200, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ming Wu Tel +86 755 83676149 Email Background: Increasing evidence indicates carbapenem-resistant Klebsiella pneumoniae (CrKP) is increasingly prevalent in intensive care unit (ICU), but its clinical characteristics and risk factors remain unknown. Aim: The aim of the present study was to evaluate clinical characteristics, risk factors in critically ill patients with CrKP infection. Methods: A retrospective study was included in patients from January 2013 to October 2019. Clinical data were collected from CrKP patients on the day of specimen collection admitted to ICU. Multivariable logistic regression was used for risk factors. Receiver operating curve (ROC) and the area under the curve (AUC) with DeLong method of MedCalc software were used. Two-way repeated-measures ANOVA analysis was used to analyze the characteristics of independent risk factors over time. Findings: A total of 147 adult patients with CrKP were screened, among them, 89 (median age 64.0 years, 66 (74.15%) males) patients with CrKP were finally included, of which 38 patients (42.7%) were non-survival group. Multivariate logistic regression analysis indicated that lactic acid (OR3.04 95% CI 1.38– 6.68, P = 0.006), APACHE II score (OR 1.20, 95% CI 1.09– 1.33, P < 0.001), tigecycline combined with fosfomycin treatment (OR0.15, 95% CI 0.04– 0.65, P = 0.011) are independent risk factors for 28-day mortality in patients with CRKP infection ( P < 0.05). Combined lactic acid with APACHE II score could predict 28-day mortality, of which AUC value was 0.916 (95% CI, 0.847– 0.985), with sensitivity 0.76 and specificity 0.98. ANOVA analysis showed that APACHE II score and lactic acid between the two groups at three-time points were statistically significant, which interactive with time and showed an upward and downward trend with time (P < 0.05). Conclusion: Therapeutic strategy based on improving lactic acid and APACHE II would contribute to the outcome in patients with CrKP infection. Tigecycline combined with fosfomycin could reduce the 28-day mortality in patients with CrKP infection in developing country. Keywords: carbapenem resistant Klebsiella pneumoniae , lactic acid, APACHE II score, tigecycline, fosfomycin, mortality Klebsiella pneumoniae (KPN) is a kind of intestinal bacteria in our surrounding environment, and is colonized in human oral cavity, respiratory tract, gastrointestinal tract and urinary tract. It is generally considered that KPN, as an opportunistic pathogen, can lead to life-threatening infection in infants or children with low immunity and elderly patients or patients taking immunosuppressants for a long time, including sepsis caused by pulmonary infection, urinary infection and blood flow infection. 1 KPN mainly obtains drug resistance through the production of antibiotic inactivating enzymes, active efflux mechanism and the formation of biofilm to resist the bactericidal activity of antibiotics. KPN produced carbapenem enzymes (classes A, B and D) and AmpC enzymes/ESBLs combined with deletion or down-regulation of outer membrane protein, which made it resistant to carbapenem antibiotics. 2 The international drug resistance network monitoring organization (INFORM) collected 45,335 strains of Gram-negative bacteria from 18 European countries/regions from 2013 to 2017, and screened 9546 isolated strains β- Lactamase. Carbapenemase was found in 3.4% of intestinal bacteria collected in Greece, but KPN w -Abstract Truncated-
pharmacology & pharmacy,infectious diseases